AbbVie Inc. $ABBV is CHICAGO TRUST Co NA’s 8th Largest Position

CHICAGO TRUST Co NA trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 10.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 59,632 shares of the company’s stock after selling 7,129 shares during the period. AbbVie makes up about 1.9% of CHICAGO TRUST Co NA’s investment portfolio, making the stock its 8th largest holding. CHICAGO TRUST Co NA’s holdings in AbbVie were worth $13,807,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new stake in AbbVie in the 2nd quarter worth about $4,288,200,000. Laurel Wealth Advisors LLC lifted its stake in AbbVie by 18,384.4% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after acquiring an additional 5,675,095 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of AbbVie by 550.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after acquiring an additional 3,666,521 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of AbbVie by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after acquiring an additional 3,380,842 shares during the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new stake in shares of AbbVie in the second quarter worth approximately $581,817,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

NYSE:ABBV opened at $227.44 on Monday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The stock has a 50-day simple moving average of $226.63 and a two-hundred day simple moving average of $211.31. The firm has a market capitalization of $401.98 billion, a PE ratio of 172.30, a P/E/G ratio of 1.29 and a beta of 0.36. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Analysts Set New Price Targets

ABBV has been the topic of several research reports. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a report on Tuesday, November 4th. Morgan Stanley increased their price target on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Bank of America upped their price objective on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, JPMorgan Chase & Co. raised their target price on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.